Nearly 1 in 4 babies in NICUs receive acid suppressing medication

April 27, 2016

Since 2006, several published studies have associated the use of some acid suppression medications in hospitalized high-risk babies with infections, necrotizing enterocolitis and increased risk of death. Those medications - histamine-2 receptor antagonists such as ranitidine (Zantac and others), and proton pump inhibitors such as esomeprazole (Nexium and others) - were originally approved by the U.S. Food and Drug Administration for use in adults and older children.

Though not approved for use in newborns, doctors prescribe the drugs to treat gastroesophageal reflux disease (GERD) and to help with other conditions diagnosed in neonatal intensive care units (NICUs). A study out online today in The Journal of Pediatrics, led by physicians and researchers at Nationwide Children's Hospital shows just how frequently the drugs have been prescribed for those newborns at 43 children's hospitals across the country.

From January 2006 through March 2013, 28,989 of 122,002 of babies, or 23.8%, received a histamine-2 receptor antagonist or proton pump inhibitor. Babies diagnosed with GERD, congenital heart disease and ear, nose and throat conditions were the most likely to be prescribed the medications.

"The number is surprising, because there are now multiple studies that say these drugs are associated with harmful effects," said Jonathan L. Slaughter, MD, MPH, lead author of the study and neonatologist at Nationwide Children's. "There's actually little evidence that acid suppression helps in the NICU at all."

Some amount of stomach acid likely protects these babies, who have compromised immune systems, from harmful bacteria, according to Dr. Slaughter, who is also a principal investigator in the Center for Perinatal Research in The Research Institute at Nationwide Children's and an assistant professor of Pediatrics at The Ohio State University College of Medicine.

"GERD itself is over-diagnosed without complete testing," Dr. Slaughter said. "When reflux is present, reduction of acid alone does not prevent the reflux. Many symptoms commonly associated with GERD in preterm infants, such as breathing problems, are often simply due to immaturity."

The study authors found that the percentage of babies treated with histamine-2 receptor antagonists declined from 2006 to 2013, and while the percentage of babies treated with proton pump inhibitors rose until 2010, it declined afterward.

"It's encouraging that doctors are starting to pay attention to the warnings and decrease usage," Dr. Slaughter said. "In the small premature babies who are prescribed acid suppressive medications, doctors are waiting longer, until they are a little older. That's promising. But I think the numbers should be declining faster, and the research community should continue to devote resources to study the drugs' effectiveness and safety."

Most babies who are treated with the suppressive medications in the NICU continue to take them at discharge from the hospital, the study found. Doctors should consider a plan to wean the babies before they leave, Dr. Slaughter said. Among other reasons, parents want to know that their children can eventually stop the medicine.

"Parents are right to ask questions and voice concerns about starting the drugs, or about the timetable for stopping," Dr. Slaughter said. "Parents should not be afraid to ask about evidence for the medications working or about possible side effects."

Neonatologists at Nationwide Children's use acid suppressive medications in limited circumstances only after confirmation of GERD following testing, and work with the hospital's associated NICUs to ensure that only babies who can be helped by them receive them, according to Dr. Slaughter.
-end-
Reference:

Slaughter J, Stenger M, Reagan P, Jadcherla S. Neonatal histamine-2 receptor antagonist and proton pump inhibitor treatment at United States Children's Hospitals. The Journal of Pediatrics. 2016 April 27. [Epub ahead of print]

Nationwide Children's Hospital

Related Necrotizing Enterocolitis Articles from Brightsurf:

Antibiotics affect breast milk microbiota in mothers of preterm infants: University of Toronto study
A team led by researchers at the University of Toronto and The Hospital for Sick Children has found that mothers of preterm babies have highly individual breast milk microbiomes, and that even short courses of antibiotics have prolonged effects on the diversity and abundance of microbes in their milk.

Human milk based fortifiers improve health outcomes for the smallest premature babies
More than 380,000 babies are born prematurely in the United States each year, according to the March of Dimes.

New machine learning tool predicts devastating intestinal disease in premature infants
Researchers from Columbia Engineering and the University of Pittsburgh have developed a sensitive and specific early warning system for predicting necrotizing enterocolitis (NEC) in premature infants before the life-threatening intestinal disease occurs.

AGA does not recommend the use of probiotics for most digestive conditions
After a detailed review of available literature, the American Gastroenterological Association (AGA) has released new clinical guidelines finding that for most digestive conditions there is not enough evidence to support the use of probiotics.

Children with food protein-induced enterocolitis more likely to have other allergies
Researchers at Children's Hospital of Philadelphia (CHOP) have found that children with a rare food allergy known as food protein-induced enterocolitis syndrome, or FPIES, have a significantly higher chance of being diagnosed with other allergic conditions, including eczema, traditional food allergy and asthma.

Scientists discover the origin of a microbial infection with lethal effects
When the bacterium Aeromonas hydrophila penetrates the organism through a tissue it gives rise to necrotizing fasciitis, a serious infection that attacks the tissues and in a few hours can even lead to the death of the patient.

Study shows biomarker accurately diagnoses deadly infant disease
A diagnostic study of 136 premature infants found that a protein involved in managing harmful bacteria in the human intestine is a reliable biomarker for the noninvasive detection of necrotizing enterocolitis (NEC).

State initiative to address disparities in mother's milk for very low birth weight infants
A new study, published in Pediatrics, indicates that the initiative yielded positive results on improving rates of prenatal human milk education, early milk expression and skin to skin care among mothers of very low birth weight infants during initial hospitalization, but did not lead to sustained improvement in mother's milk provision at hospital discharge.

Milk expression within 8 hours associated with lactation success for VLBW infants in NICU
A study led by physician researchers at Boston Medical Center has shown that first milk expression within eight hours of giving birth is associated with the highest probability of mothers of very low-birth-weight infants being able to provide milk throughout hospitalization in the neonatal intensive care unit.

Cutting-edge discovery points to potential treatment for NEC in preemies
Cutting-edge discovery in the lab of Catherine Hunter, MD, from Stanley Manne Children's Research Institute at Ann & Robert H.

Read More: Necrotizing Enterocolitis News and Necrotizing Enterocolitis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.